Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $105.25.

Several brokerages have recently issued reports on CELC. Jefferies Financial Group boosted their price objective on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Wells Fargo & Company started coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target for the company. HC Wainwright restated a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Craig Hallum lifted their price objective on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This trade represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 15.78% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Celcuity in the third quarter worth about $27,000. US Bancorp DE boosted its holdings in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets grew its position in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Celcuity during the third quarter worth $79,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Stock Down 1.6%

CELC opened at $99.92 on Wednesday. Celcuity has a 12 month low of $7.57 and a 12 month high of $112.64. The business has a 50-day moving average of $91.86 and a two-hundred day moving average of $57.21. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of -27.23 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. On average, research analysts expect that Celcuity will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.